How Much Does Evenity (Romosozumab) Cost in South Carolina in 2026?

Evenity List Price and Cash-Pay Cost in South Carolina

The manufacturer list price for a single 210 mg dose of Evenity sits at $1,825 in 2026, and South Carolina retail pharmacies reflect this same figure as the average cash-pay price. A complete 12-month treatment course therefore runs approximately $21,900 before any discounts or insurance adjustments.

This pricing has remained relatively stable since the drug's FDA approval in April 2019. Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation. The ARCH trial (N=4,093) demonstrated that romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months, making it one of the most effective anabolic agents available for severe osteoporosis. That clinical benefit comes at a price point that places it among the most expensive osteoporosis therapies on the market.

Cash-pay patients in South Carolina who fill at a specialty pharmacy rather than a standard retail outlet may occasionally find slightly lower pricing through discount aggregators. GoodRx and similar platforms sometimes list Evenity at $1,750 to $1,820 per dose, though availability varies by pharmacy location. The savings from shopping around without insurance are modest at best. For most patients paying out of pocket, the full course remains a five-figure expense.

South Carolina Medicaid Does Not Cover Evenity

South Carolina's Medicaid program does not include Evenity on its preferred drug list, even for patients with severe osteoporosis or prior fragility fractures. This gap affects a significant population: according to the CDC's National Center for Health Statistics, roughly 10.6% of adults aged 50 and older in the United States have osteoporosis at the femoral neck, and Medicaid enrollees skew toward populations with more limited access to first-line screening and early intervention.

Patients on SC Medicaid who need an anabolic bone agent face limited alternatives. Teriparatide (Forteo) and abaloparatide (Tymlos) are parathyroid hormone analogs that may have different formulary status, but coverage varies by managed care plan. A prescribing physician can file an exception request or prior authorization appeal through SC Healthy Connections Medicaid, though approval rates for non-formulary specialty biologics remain low without strong documentation of treatment failure on covered alternatives.

For SC Medicaid enrollees denied coverage, the Amgen Safety Net Foundation offers a separate patient assistance program (distinct from the commercial savings card) that provides Evenity at no cost to qualifying patients with household incomes at or below 300% of the federal poverty level. Application requires proof of insurance denial and income documentation.

Commercial Insurance Coverage Pathways in South Carolina

Most major commercial insurers operating in South Carolina, including BlueCross BlueShield of South Carolina, Cigna, Aetna, and UnitedHealthcare, cover Evenity under their specialty pharmacy tiers. Coverage is not automatic. Prior authorization is required in nearly every case, and the insurer's clinical criteria typically demand at least two of the following:

• A DXA-confirmed T-score of <-2.5 at the hip or lumbar spine
• A history of fragility fracture (vertebral or hip)
• Documented failure of, intolerance to, or contraindication for an oral bisphosphonate such as alendronate or risedronate
• A 10-year FRAX score exceeding the National Osteoporosis Foundation's intervention threshold

The Endocrine Society's 2020 clinical practice guideline recommends anabolic therapy as initial treatment in patients at very high fracture risk, which provides supporting documentation for prior authorization submissions. Dr. Clifford Rosen, a senior scientist at Maine Medical Center Research Institute and contributor to Endocrine Society guidelines, has stated: "For patients with recent vertebral fractures or T-scores below minus 3.0, starting with an anabolic agent rather than an antiresorptive represents the most effective sequence to reduce fracture risk."

Step therapy requirements are common. BlueCross BlueShield of SC, the state's dominant insurer, generally requires a trial of at least one bisphosphonate before approving romosozumab. UnitedHealthcare's 2026 policy permits first-line anabolic therapy only when the patient has sustained two or more vertebral fractures or a hip fracture within the preceding 24 months. Approval timelines range from 5 to 21 business days, and denials can be appealed with additional clinical documentation.

Out-of-pocket costs after insurance approval depend on the plan's specialty tier. Patients on high-deductible plans may still face $500 to $1,200 per dose until meeting their deductible, while those with specialty copay structures typically see $100 to $400 per injection before applying manufacturer copay assistance.

How the Amgen/UCB Savings Card Works in South Carolina

The Evenity copay savings card, offered jointly by Amgen and UCB, is available to commercially insured patients in South Carolina and can reduce out-of-pocket costs to $0 per dose for eligible individuals. The card covers up to $1,825 per month in copay or coinsurance charges, which effectively zeroes out the patient's share for most commercial plans.

Eligibility requirements are straightforward. Patients must have commercial insurance that covers Evenity, must not be enrolled in any federal or state government program (Medicare, Medicaid, Tricare, VA), and must be a resident of the United States. The card is valid for up to 24 uses, which exceeds the standard 12-dose treatment course and allows for potential treatment interruptions or restarts.

Enrollment is handled through the Evenity Complete portal or by phone. The prescribing physician's office can also enroll patients directly during the prior authorization process. Once enrolled, the savings card is applied at the specialty pharmacy as a secondary payer. There is no income threshold for the commercial savings card program.

One limitation applies. Patients with Medicare Part D as primary coverage cannot use the manufacturer copay card due to federal anti-kickback regulations. Medicare beneficiaries in South Carolina face potentially steep Part D specialty-tier copays of 25% to 33% coinsurance during the initial coverage phase, which translates to roughly $456 to $602 per monthly injection before reaching the catastrophic coverage threshold.

Compounded Romosozumab Through 503A Pharmacies in South Carolina

Licensed 503A compounding pharmacies in South Carolina can legally prepare compounded romosozumab for individual patients with valid prescriptions. This pathway exists under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding when a prescriber determines that a commercially manufactured product does not meet a patient's medical needs.

A critical distinction is necessary here. Compounded biologics are not FDA-approved, not subject to the same manufacturing standards as branded Evenity, and not evaluated for bioequivalence. The FDA has issued guidance noting that compounded drugs are not reviewed for safety, efficacy, or quality in the same manner as approved drugs. The American Association of Clinical Endocrinology (AACE) has not endorsed compounded biosimilar monoclonal antibodies as substitutes for FDA-approved products.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital, has cautioned: "Monoclonal antibodies like romosozumab have complex tertiary protein structures that are difficult to replicate outside validated manufacturing processes. Patients considering compounded versions should understand that potency, sterility, and efficacy may differ meaningfully from the branded product."

Pricing at 503A pharmacies varies widely. Some compounders list romosozumab preparations at dramatically lower costs than the branded product, but patients should verify that the pharmacy holds a valid South Carolina Board of Pharmacy compounding license and meets USP 797 and USP 800 standards. The South Carolina Department of Health and Environmental Control (DHEC) maintains a searchable database of licensed pharmacies.

Telehealth Prescribing of Evenity in South Carolina

South Carolina permits telehealth prescribing of Evenity under both state telemedicine statutes and the SC Board of Medical Examiners' regulations. A physician licensed in South Carolina can evaluate a patient via synchronous audio-video visit, review DXA results and laboratory values, and prescribe romosozumab without requiring an in-person encounter.

This access pathway is particularly relevant for patients in rural parts of the state. Roughly 33 of South Carolina's 46 counties are classified as medically underserved or have health professional shortage areas according to HRSA data. Telehealth eliminates the travel burden for patients who may be hours from the nearest endocrinologist or rheumatologist with bone health expertise.

The injection itself does require in-person administration. Evenity is delivered as two subcutaneous injections (each containing 105 mg in 1.17 mL) given sequentially at the same clinical visit. Patients can receive injections at their local primary care office, an infusion center, or a home health nursing visit, even when the prescribing relationship is maintained via telehealth.

Comparing Evenity Costs to Other Osteoporosis Therapies in South Carolina

Evenity's $1,825 monthly price point positions it at the upper end of osteoporosis treatments available in South Carolina. For context, consider these approximate 2026 cash-pay costs across the state:

Generic alendronate (oral bisphosphonate) runs $10 to $30 per month. Zoledronic acid (IV bisphosphonate, given annually) costs $300 to $700 per infusion. Denosumab (Prolia, given every 6 months) averages $1,400 to $1,700 per injection. Teriparatide (Forteo, daily injection for 24 months) carries a list price near $3,900 per month, and abaloparatide (Tymlos, daily injection for 24 months) lists at approximately $3,200 per month.

On a per-course basis, romosozumab's 12-month regimen at $21,900 actually costs less than a full course of Forteo ($93,600 over 24 months) or Tymlos ($76,800 over 24 months). The FRAME trial (N=7,180) and ARCH trial both demonstrated rapid bone mineral density gains with romosozumab. In ARCH, patients receiving romosozumab followed by alendronate had a 48% lower risk of new vertebral fracture at 24 months compared to those receiving alendronate alone [1]. The speed of BMD accrual with romosozumab is notable: mean lumbar spine BMD increased by 13.7% at 12 months in the FRAME extension study, exceeding gains seen with any other single agent.

The cardiovascular black box warning on Evenity does narrow the eligible population. Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year, and prescribers must weigh cardiovascular risk factors before initiating therapy. This safety consideration, documented in the FDA label, can redirect some patients toward teriparatide or abaloparatide despite those agents' higher total course costs.

Discount Programs and Financial Assistance Options for SC Patients

Beyond the manufacturer copay card, several additional programs can reduce Evenity costs for South Carolina residents:

The Amgen Safety Net Foundation provides free Evenity to uninsured or underinsured patients who meet income requirements (household income at or below 300% of the federal poverty level, which is $46,800 for a single individual in 2026). The application requires documentation of insurance denial or lack of coverage and takes 2 to 4 weeks for processing.

The Patient Access Network (PAN) Foundation periodically opens funding cycles for osteoporosis therapies that can help Medicare patients cover Part D copays. Fund availability fluctuates, and patients should check panfoundation.org for current status.

Specialty pharmacies with hub services, such as Accredo, AllianceRx Walgreens, and Optum Specialty, may offer additional navigation support for patients in South Carolina who face complex prior authorization requirements or need help identifying alternative funding.

For patients who exhaust all assistance options, some SC-based endocrinology and rheumatology practices participate in buy-and-bill arrangements where the practice purchases Evenity directly and bills the insurer under medical benefit (J-code J3590 or specific romosozumab codes), which may yield different cost-sharing than pharmacy benefit billing.